Cardiac stem and progenitor cell biology for regenerative medicine

Abstract

Stem cell therapy is a new and promising treatment of heart disease. However, the race is still on to find the "best" cell to reconstitute the myocardium and improve function after myocardial damage. The recent discovery in the adult mammalian myocardium of a small cell population with the phenotype, behavior, and regenerative potential of cardiac stem and progenitor cells has proposed these cells as the most appropriate for cell therapy. The existence of these cells has provided an explanation for the hitherto unexplained existence of a subpopulation of immature cycling myocytes in the adult myocardium. These findings have placed the heart squarely among other organs with regenerative potential despite the fact that the working myocardium is mainly constituted of terminally differentiated cells. Although CSCs (cardiac cells proven to have stem and/or progenitor characteristics) can be isolated and amplified in vitro or stimulated to differentiate in situ, it has become reasonable to exploit this endogenous regenerative potential to replace the lost muscle with autologous functional myocardium. Therefore, it is imperative to obtain a better understanding of the biology and regenerative potential of the endogenous CSCs. This will enable us to design better protocols for the regeneration of functional contractile mass after myocardial injury.